<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03926663</url>
  </required_header>
  <id_info>
    <org_study_id>FMBSUREC/05032019/Moselhy</org_study_id>
    <nct_id>NCT03926663</nct_id>
  </id_info>
  <brief_title>Intranasal Injection of Dexmedetomidine and Bupivacaine in Septoplasty Surgeries</brief_title>
  <official_title>Effects of Intranasal Injection of Dexmedetomidine Plus Bupivacaine on Anesthesia &amp; Analgesia in Septoplasty Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain is particularly common after nasal surgery, especially when bone manipulation and
      periosteal irritation are involved. Appropriate pain control is an important consideration in
      the post-surgical management of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple researches and clinical observations suggest that pain reduction can be achieved in
      nasal surgery by using local anesthesia.The combination of local anesthetic infiltration,
      directly in the surgical field, with general anesthesia provides beneficial analgesic effects
      by blocking nociceptive pathways, and there by it reduces the need for systemic analgesics.

      The use of α-2 Adrenergic receptor (adrenoceptor) agonists in anesthesia were the focus of
      interest for their sedative, analgesic, and perioperative sympatholytic and cardiovascular
      stabilizing effects with reduced anesthetic requirements. α-2 agonists, inhibit substance P
      release in the nociceptive pathway at the level of the dorsal root neuron; in addition, α-2
      adrenergic receptors located at nerve endings may have a role in the analgesic effect of the
      drug by preventing norepinephrine release.

      In this study, the combined effects of dexmedetomidine with bupivacaine as local anesthetics
      vs bupivacaine, will be investigated in septoplasty to determine the need for rescue drugs as
      propanlol and nitroglycerine, as hypotensive agents,for bloodless surgical field and optimal
      procedure for pain control
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2019</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The precentage of patients that will take rescue drugs as nitroglycerin, propranolol.</measure>
    <time_frame>3 hours</time_frame>
    <description>the number of patients that will need rescue drugs: propranolol 1mg will be given then after 15 minutes (with no improvement of the surgical field) nitroglycerin (NTG) infusion will be added in a titrated manner 0.1-0.5 μg/kg/min gradually till the target MAP (±60 mmHg) is reached.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Intranasal Dexmedetomidine</condition>
  <condition>Intranasal Bupivacaine</condition>
  <condition>Septoplasty Surgeries</condition>
  <arm_group>
    <arm_group_label>group Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) as preincisional local infiltration of the nasal mucosa of the nasal septum ,injected once before surgical intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group Bupivacaine +Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group B+D; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa of the nasal septum,injected once before surgical intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine, a potent α-2 adrenoceptor agonist, is approximately 8 times more selective toward the α-2 adrenoceptors than clonidine.
Patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa.</description>
    <arm_group_label>group Bupivacaine +Dexmedetomidine</arm_group_label>
    <other_name>Precedex,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) preincisional local infiltration of the nasal mucosa.</description>
    <arm_group_label>group Bupivacaine</arm_group_label>
    <arm_group_label>group Bupivacaine +Dexmedetomidine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged from 18- 60 years

          -  ASA physical status I

          -  Undergoing septoplasty

        Exclusion Criteria:

          -  Patients with cardiovascular disease (congestive heart failure, coronary artery
             disease, hypertension.

          -  History of renal or hepatic insufficiency

          -  Endocrinal Diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohamed Moselhy, MD</last_name>
    <phone>+201145504361</phone>
    <email>Mosobing@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marwa Zayed, MD</last_name>
    <phone>01005059706</phone>
    <email>marwa.zayed@kasralainy.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of medicine,Beni-Suef University</name>
      <address>
        <city>Banī Suwayf</city>
        <zip>62511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Moselhy, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Marwa Zayed</investigator_full_name>
    <investigator_title>Lecturer of anesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

